DSM Biologics and Crucell Announce PER.C6® Licensing Deal With LFB Biotechnologies.

DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research licensing agreement with Paris, France-based LFB Biotechnologies. LFB Biotechnologies will use Crucell’s technology to develop undisclosed antibodies. No financial details were disclosed.

During the research license period, Crucell and LFB Biotechnologies will also evaluate a joint collaboration in the field of enhancing sugar structures, described as glycosylation patterns, on recombinant antibodies using LFB’s in-house developed technology.

About the PER.C6® Technology Platform
Crucell’s and DSM’s PER.C6® technology platform has been developed for the large-scale manufacture of biopharmaceutical products including vaccines. Compared to conventional production technologies, the strengths of the PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

About LFB Group
The LFB Group’s mission is to develop, manufacture and market plasma-derived medicinal products and biotherapeutic proteins. Created in 1994, LFB is a public limited company with the French state as a majority shareholder. Based in France, the LFB is the 3rd pharmaceutical group supplying drugs to hospitals in France. LFB SA is a French pharmaceutical company comprised of a holding company and two operating subsidiaries:
- LFB BIOMEDICAMENTS, 1100 employees, produces and markets a wide range of plasma-derived medicinal products.
- LFB BIOTECHNOLOGIES, 200 employees, is dedicated to the group’s biotechnological activities and new medicinal products Research & Development.

LFB S.A. currently has three foreign subsidiaries: LFB Hemoderivados in Brazil, LFB Biopharmaceuticals Ltd in the United Kingdom and LFB GmbH in Germany.
The LFB is ideally placed to become a driving force in new technological and therapeutic fields. LFB focuses its discovery and development activities on monoclonal antibodies and therapeutic proteins for rare and severe diseases mixing and synergising different technologies: plasma purification, cell culture, transgenic production. LFB uses Emabling®, its technology platform, to develop highly functionally optimized antibodies while its R & D portfolio contains high-potential projects calling on innovative technology. For more information about the LFB Group, you can visit http://www.lfb.fr